# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA 40211

2: Name of authorisation holder SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, THE BRUCE BUILDING, CASTLE BUSINESS PARK, STIRLING, FK9 4TS, UNITED

KINGDOM

3: Address(es) of manufacturing site(s)

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, SCION

HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9

4NF, UNITED KINGDOM

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, UNIT 10,

4: Legally registered address of authorisation holder SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK,

STIRLING, FK9 4NF, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

6: Legal Basis of authorisation

Regulation 17 of The Human Medicines Regulations 2012 (SI

2012/1916)

7: Name of responsible officer of the competent authority

of the member state granting the manufacturing Confidential

authorisation

8: Authorisation Date 29/07/2025

9: Annexes attached Annex 1 and/or Annex 2

### SCOPE OF AUTHORISATION

#### Annex 1

Name and address of the site:

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, THE BRUCE BUILDING, CASTLE BUSINESS PARK, STIRLING, FK9 4TS, UNITED KINGDOM

**Human Medicinal Products** 

**Authorised Operations** 

MANUFACTURING OPERATIONS (according to part 1)

IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

#### Part 1 - MANUFACTURING OPERATIONS

### [ 1.1 ] Sterile Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

Issue Date: 29 Jul 2025

[1.1.1.4] Small volume liquids Special Requirements Cytotoxics [ 1.1.1.6 ] Other aseptically prepared products Suspensions **Special Requirements** Cytotoxics [ 1.3 ] Biological medicinal products [ 1.3.1 ] Biological medicinal products [ 1.3.1.2 ] Immunological products [1.3.1.3] Cell therapy products [1.3.1.4] Gene therapy products [ 1.3.1.5 ] Biotechnology products [ 1.3.1.8 ] Other biological medicinal products Plasmid, DNA, RNA, peptides, proteins and antibody products. Special Requirements Cytotoxics [ 1.4 ] Other products or manufacturing activity [ 1.4.2 ] Sterilisation of active substances/excipients/finished products: [ 1.4.2.1 ] Filtration [ 1.5 ] Packaging [1.5.2] Secondary packaging [ 1.6 ] Quality control testing [ 1.6.2 ] Microbiological: non-sterility Part 2 - IMPORTATION OF MEDICINAL PRODUCTS [ 2.2 ] Batch certification of imported medicinal products [2.2.3] Biological medicinal products

[2.2.3.4] Gene therapy products

### [ 2.3 ] Other Importation Activities

[2.3.1] Site of Physical Importation

[ 2.3.2 ] Importation of Intermediate which undergoes further processing

#### SCOPE OF AUTHORISATION

#### Annex 1

Name and address of the site:

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM

**Human Medicinal Products** 

**Authorised Operations** 

MANUFACTURING OPERATIONS (according to part 1)

IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

Issue Date: 29 Jul 2025

#### Part 1 - MANUFACTURING OPERATIONS

#### [ 1.1 ] Sterile Products

[ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.2] Lyophilisates

[ 1.1.1.4 ] Small volume liquids

## Special Requirements

Cytotoxics

#### [ 1.3 ] Biological medicinal products

[1.3.1] Biological medicinal products

[1.3.1.4] Gene therapy products

[1.3.1.5] Biotechnology products

#### [ 1.4 ] Other products or manufacturing activity

[ 1.4.2 ] Sterilisation of active substances/excipients/finished products:

[ 1.4.2.1 ] Filtration

Part 2 - IMPORTATION OF MEDICINAL PRODUCTS

#### [ 2.2 ] Batch certification of imported medicinal products

[ 2.2.3 ] Biological medicinal products

[2.2.3.4] Gene therapy products

#### [ 2.3 ] Other Importation Activities

[2.3.1] Site of Physical Importation

[2.3.2] Importation of Intermediate which undergoes further processing



Manufacturer's Authorisation: UK MIA 40211 Page 3 of 3 Issue Date: 29 Jul 2025